Evidence map›Paper›PMID 41465855›Full record

ArticleLife (Basel, Switzerland)2025

The Impact of Decreased GSK3β and S6K1 Expression in TNBC Patients.

Tijana Tomić, Mirjana Prvanović, Jovan Jevtić, Blagoje Murganić, Nejla Ademović, Milica Nedeljković, Irena Jovanić, Nikola Tanić, Nasta Tanić

Abstract read
In one paragraph

Article in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tijana TomićDepartment of Radiobiology and Molecular Genetics, Institute of Nuclear Sciences "Vinča", National Institute of Republic of Serbia, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0002-2111-8687
Mirjana PrvanovićInstitute of Pathology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0009-0005-1714-4363
Jovan JevtićInstitute of Pathology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0002-3424-4623
Blagoje MurganićDepartment of Radiobiology and Molecular Genetics, Institute of Nuclear Sciences "Vinča", National Institute of Republic of Serbia, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0003-2289-946X
Nejla AdemovićDepartment of Neurobiology, Institute for Biological Research "Siniša Stanković", National Institute of Republic of Serbia, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0001-8275-1294
Milica NedeljkovićDepartment of Experimental Oncology, Institute of Oncology and Radiology of Serbia, 11000 Belgrade, Serbia.ORCID 0000-0003-0153-3901
Irena JovanićDepartment of Pathology, Institute of Oncology and Radiology of Serbia, 11000 Belgrade, Serbia.
Nikola TanićDepartment of Neurobiology, Institute for Biological Research "Siniša Stanković", National Institute of Republic of Serbia, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0001-5817-7763
Nasta TanićDepartment of Radiobiology and Molecular Genetics, Institute of Nuclear Sciences "Vinča", National Institute of Republic of Serbia, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0002-5740-4140

Funding

Ministry of Science, Technological Development, and Innovations of the Republic of Serbia 451-03-136/2025-03/200007Ministry of Science, Technological Development, and Innovations of the Republic of Serbia 451-03-136/2025-03/200017
6 · The paper itself

Abstract

Breast cancer is the most frequent and lethal type of cancer that affects women worldwide. Triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer, having high rate of recurrence, metastasis, and mortality, with very limited options for treatment, and a tendency to develop resistance to conventional therapy. These circumstances mean that it is necessary to develop effective therapies for TNBC patients which would circumvent resistance mechanisms. The PAM and Wnt signaling pathways are among those responsible for therapy resistance in TNBC, as they also have major roles in different cellular processes such as metabolism, proliferation, metastasis, stemness, and survival. We analysed the expression of GSK3β and S6K1 as interacting components of the two pathways in order to examine the relation between them and determine whether they could be used as predictive markers in TNBC. The expression of mRNA was examined with real-time PCR and protein expression with immunohistochemistry. Our results showed that protein expression is in line with mRNA expression. We found a positive correlation between the mRNA expressions of GSK3β and S6K1, showing their coordinated transcription. We also showed that their simultaneous low expression is unfavorable for TNBC patients and could possibly be used as a predictive marker.

Indexed as

GSK3βIHCmRNA expressionS6K1TNBC

Identifiers

PMID41465855
PMCPMC12734461

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.